Torii Pharmaceutical Co Ltd (4551.T)

4551.T on Tokyo Stock Exchange

11:30am IST
Change (% chg)

¥-5 (-0.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Menlo Therapeutics signs license agreement with Japan Tobacco, Torii Pharma for NK-1 receptor antagonist
Wednesday, 10 Aug 2016 

Menlo Therapeutics Inc : Menlo Therapeutics signs exclusive license agreement with Japan Tobacco and Torii Pharmaceuticals for development and commercialization of NK-1 receptor antagonist in Japan . Entered into license agreement with Japan Tobacco Inc. and Torii Pharmaceutical for development,commercialization of serlopitant in Japan .JT,Torii to pay co upfront licensing fees,payments upon achievement of certain milestones, royalties based on future sales in Japan.  Full Article

BRIEF-Torii Pharmaceutical says new drug application approval of allergen immunotherapy tablet for japanese cedar pollinosis

* Says the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of "CEDARCURE® Japanese Cedar Pollen Sublingual Tablets", an allergen immunotherapy tablet for Japanese cedar pollinosis